Jasper Therapeutics, Inc. (JSPRW) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$77.16M | -23.3% |
| 2024 | -$62.60M | -20.2% |
| 2023 | -$52.07M | -13.5% |
| 2022 | -$45.86M | -36.2% |
| 2021 | -$33.68M | -84.4% |
| 2020 | -$18.27M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$77.16M | -23.3% |
| 2024 | -$62.60M | -20.2% |
| 2023 | -$52.07M | -13.5% |
| 2022 | -$45.86M | -36.2% |
| 2021 | -$33.68M | -84.4% |
| 2020 | -$18.27M | — |